Abstract 1135P
Background
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer of the skin, characterized by a high propensity for metastasis and a dismal prognosis particularly for advanced tumor stages. Immune-checkpoint blockade (ICB) is effective in MCC, but 60% of patients show primary or acquired resistance. Predictive biomarkers for the risk of metastasis and response to ICB are lacking. We studied the tumor microenvironment (TME) of 60 MCC patients to identify molecular mechanisms associated with response to ICB and profile the temporal dynamics occurring during tumor progression.
Methods
We collected 115 tissue biopsies from this MCC cohort with detailed clinical documentation and longitudinal follow-up and profiled the TME with high-plex imaging and matched bulk RNAseq that was collected from consecutive sections using laser-capture microdissection. We integrated clinical and molecular data and explored biomarkers using a lasso regressed CoxPH model.
Results
Our multi-modal data integration framework identified Merkel cell polyomavirus positivity, the abundance of CD8+ T cells and PD-L1+ macrophages as independent determinants of metastasis-free survival (DMFS), while the enrichment of cancer-associated fibroblasts at the tumor boundary correlated with distant metastasis. Response to ICB was correlated with the presence of central memory T cells (TCM), and Follicle-like cellular neighborhoods as well as a PD-L1+ tumor phenotype, that associated with an inflammatory macrophage signature (CXCL9, CXCL10, CXCL13) specifically at the tumor invasive front. By contrast, ICB failure associated with a cancer-stem phenotype (SOX2, NELL) and the downregulation of type-II interferon signaling (STAT1, JAK1). Last, we identified that exacerbation of T cell exhaustion, loss of TCM and inflammatory macrophages are critical elements of MCC evolutionary progression.
Conclusions
We demonstrate that high dimensional imaging of the MCC TME provides a framework to interrogate cellular interactions and tissue architecture in-situ at single-cell resolution. This framework enabled to identify genomic and phenotypic correlates for distant metastasis and response to ICB and map evolutionary changes during tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Deutsche Forschungsgemeinschaft.
Disclosure
G. Nolan: Financial Interests, Personal, Stocks or ownership: Akoya Bio. All other authors have declared no conflicts of interest.
Resources from the same session
1074TiP - A phase I study of GIGA-564, a minimally blocking anti-CTLA-4 monoclonal antibody
Presenter: James Gulley
Session: Poster session 04
1075TiP - A phase I trial of ATG-101, an investigational PD-L1×4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN
Presenter: Junli Xue
Session: Poster session 04
Resources:
Abstract
1083P - KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Presenter: Reinhard Dummer
Session: Poster session 04
1084P - Phase II study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
Presenter: Muhammad Khattak
Session: Poster session 04
1085P - Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial
Presenter: Brigit van Dijk
Session: Poster session 04
1086P - Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial
Presenter: Manon Vounckx
Session: Poster session 04
1087P - Phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations
Presenter: Kevin Kim
Session: Poster session 04
1088P - Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study
Presenter: Andrea Boutros
Session: Poster session 04
1089P - Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
Presenter: Elizabeth Burton
Session: Poster session 04
Resources:
Abstract
1090P - High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma
Presenter: Lotte Hoeijmakers
Session: Poster session 04